Share
The world’s first gene therapy trial for a genetic cause of blindness known as choroideremia has shown positive results.
The trial, supported by NIHR Oxford Biomedical Research Centre (BRC), began in 2011 at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Foundation Trust.
Reported on Monday 8 October in the Nature Medicine journal, the trial involved 14 patients receiving a single injection into the back of the eye of a virus containing the missing gene. By the end of the study there was a significant gain in vision across the group of patients as a whole.
Furthermore, of the 12 patients who received the treatment without any complications, 100 per cent either gained or maintained vision in their treated eyes, which was sustained for up to five years at the last follow up.
During this time only 25 per cent of the untreated eyes that acted as controls maintained vision.
The gene therapy treatment was generally well tolerated and there were no significant safety concerns.
The trial was led by ophthalmologist Prof Robert MacLaren, the Oxford BRC theme lead for Surgical Innovation. He said: “The early results of vision improvement we saw have been sustained for as long as we have been following up these patients and in several the gene therapy injection was over 5 years ago. The trial has made a big difference to their lives.”
The success of the Oxford study has led to a much larger international gene therapy trial involving over 100 patients across nine countries in the EU and in North America. It is now led by Nightstar Therapeutics, a gene therapy spin-out company established by the University of Oxford and Syncona to develop the treatment further.
If successful the follow-on trial could result in the gene therapy treatment being formally approved by the relevant regulatory bodies worldwide.
Overall gene therapy is a new treatment that is currently being developed in several trials for a variety of diseases. The concept of gene therapy is to alter or correct inherited diseases at the level of the DNA. If successful, a single treatment might have life-long effects.
These early results support the notion that a single gene correction can have long-lasting beneficial effects on nerve cells of the retina to prevent blindness.
Choroideremia is one disease in a spectrum of inherited eye diseases sometimes referred to as ‘retinitis pigmentosa’. These have become the most common cause of untreatable blindness in young people.
Last month, the European Medicines Agency formally approved its first gene therapy treatment for a different eye disease. Experts predict that other currently incurable diseases are likely to follow and will have approved gene therapy treatments in future years.
Dr Neil Ebenezer, Director of Research, Policy and Innovation at Fight for Sight, said: “All research breakthroughs are made by standing on the shoulders of others. Our mission is to fund research that will stop sight loss and we’re delighted to have been part of this breakthrough which will have huge benefits for the future. This technique could transform how we treat diseases and could have broad applicability to a range of other conditions.”
Chris Hollowood, Chief Investment Officer at Syncona, commented: “Nature Medicine’s publication of the findings of the first choroideremia gene therapy trial is a great endorsement of the work by Professor Robert Maclaren and the team and validation of the early results that encouraged Syncona to partner with Robert to found and build Nightstar.
“Since then, Nightstar has advanced the therapy to a pivotal Phase 3 trial. We look forward to continuing our support of Robert and Nightstar as we seek to bring transformational treatments to patients.”